Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)
Last updated:
Last updated
The date of the most recent update for each trial record in the Canadian Clinical Trial Search Portal.
2026-07-11
Language and content disclaimer
The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.
Linking to Non-Government of Canada Websites
Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.
Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.
A PHASE 3, RANDOMIZED OPEN-LABEL STUDY OF PEMBROLIZUMAB (MK-3475) PLUS OLAPARIB VERSUS ABIRATERONE ACETATE OR ENZALUTAMIDE IN PARTICIPANTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) WHO ARE UNSELECTED FOR HOMOLOGOUS RECOMBINATION REPAIR DEFECTS AND HAVE FAILED PRIOR TREATMENT WITH ONE NEXT-GENERATION HORMONAL AGENT (NHA) AND CHEMOTHERAPY (KEYLYNK-010)
Intervention/treatment:
Intervention/treatment
Name given to the drug used in the clinical trial. This may be a code name, a chemical name of the active ingredient, a non-proprietary name or brand name.
LYNPARZA (OLAPARIB) / KEYTRUDA (PEMBROLIZUMAB)
Medical condition:
Medical condition
The disease or condition that's being studied in the clinical trial.
CASTRATION RESISTANT PROSTATE CANCER
Protocol code:
Protocol Code
An alpha-numeric sequence generated by the sponsor that can vary in length. Used as a reference to help identify a specific clinical trial protocol. Formerly referred to as 'protocol number'.
MK-7339-010
Control number:
Control number
A unique 6-digit identification number Health Canada assigns to each clinical trial application.
224961
Status:
Trial Status
The status for the clinical trial as a whole. Note that the status for each site may be different and should always be confirmed with the clinical trial sponsor. Health Canada uses information provided by the sponsor to an international clinical trial registry to determine status values for each clinical trial. Status values on the portal can include:
• Not yet recruiting - Participants are not yet being recruited or enrolled at any site. • Recruiting - Participants are currently being recruited. • Active, not recruiting - The clinical trial is ongoing but new participants are not currently being recruited or enrolled. • On hold - The clinical trial has been temporarily stopped, but it may start again. • Closed - The clinical trial has either ended normally and participants are no longer being examined or treated, or it has stopped early and will not start again. • Unknown - The status of the clinical trial has not been verified in the registry in the last 2 years. Please contact the sponsor. • No match, ongoing - Please contact sponsor for status information. • Other - Please contact sponsor for status information.
Closed
Approved:
Approved
The date that the clinical trial has been determined to meet Health Canada’s regulatory requirements. For drug clinical trials, this means that a no objection letter or an authorization was issued.
April 03, 2019
Date Completed:
Date completed
The date of the last participant’s last visit in the global study. The completion date may be actual or estimated, depending what was provided to the registry. Estimated completion dates may be in the past or future.
Trial phase:
Trial phase
The stage of a clinical trial, based on factors such as the objectives of the trial and number of participants. Phase data displayed in the portal is taken from international registry data.
For more information see "Phases of drug trials" on the Definitions webpage
This is an external link. The information is not authorized by the Government of Canada.
Eligibility
Eligibility
The characteristics people must have or the requirements they must meet to participate in the clinical trial. Eligibility criteria include both inclusion criteria (must have for a person to participate) and exclusion criteria (prevent a person from participating).
Review the exact criteria from the registry or the sponsor before making a decision to participate. The following values may be available on the portal:
Sex: an eligibility criteria based on biological characteristics. Information in the portal is based on available data and will default to 'all' when no other data is available.
Age: The age a person must be to participate in the clinical trial.
Accepts Healthy Volunteers: People who do not have the disease or condition can participate in the clinical trial.
Sex:
MALE
Age
18 Years and older
Accepts healthy volunteers:
No
Contacts and locations
Contact
Contact
Information for an individual or organisation that can respond to questions about this clinical trial. This information comes from the international registry.
Name
Senior Vice President, Global Clinical Development
The sponsor conducts the clinical trial and is responsible for every aspect. For example this could be a company, a university or an individual researcher.
MERCK CANADA INC
Locations
Alberta
Cross Cancer Institute ( Site 0110)
Edmonton, Alberta, T6G 1Z2
British Columbia
BC Cancer-Kelowna - Sindi Ahluwalia Hawkins Centre ( Site 0113)
Kelowna, British Columbia, V1Y 5L3
BC Cancer-Vancouver Center ( Site 0112)
Vancouver, British Columbia, V5Z 4E6
Nova Scotia
Nova Scotia Health Authority QEII-HSC ( Site 0114)
Halifax, Nova Scotia, B3H 2Y9
Ontario
Hamilton Health Sciences-Juravinski Cancer Centre ( Site 0116)
Hamilton, Ontario, L8V 5C2
Princess Margaret Cancer Centre ( Site 0107)
Toronto, Ontario, M5G 2M9
William Osler Health System (Brampton Civic Hospital) ( Site 0121)
Brampton, Ontario, L6R 3J7
Quebec
CHUQ-Univ Laval-Hotel Dieu de Quebec ( Site 0103)
Québec, Quebec, G1R 2J6
CIUSSS de l Estrie - CHUS - Centre Hosp. Univ. Sherbrooke ( Site 0105)
Sherbrooke, Quebec, J1H 5N4
CIUSSS du Bas Saint Laurent - Hopital Regional de Rimouski ( Site 0102)
